中文产业新闻精选评分83Chinese source
武田奥普雷顿获FDA批准，用于成人1型发作性睡病NT1
武田奥普雷顿斩获FDA批准，NT1罕见嗜睡病迎来源头靶向新药
No English body on site. Use the original article link above, or open the Chinese edition for the editorial note.
武田奥普雷顿斩获FDA批准，NT1罕见嗜睡病迎来源头靶向新药
No English body on site. Use the original article link above, or open the Chinese edition for the editorial note.